Generate:Biomedicines, the Flagship Pioneering-backed antibody and programmable-biology company, filed for an IPO as it advances phase 3 programs and AI-designed antibody candidates. The filing emphasizes flagship assets including an anti-TSLP antibody in phase 3 for severe asthma and earlier programs engineered with machine learning to accelerate discovery timelines. Generate has attracted Big Pharma partnerships and multiyear collaborations, and the S-1 frames proceeds as funding to push lead assets through late-stage trials and to broaden the AI-enabled discovery pipeline. The company's strategy underscores a growing investor appetite for AI-driven drug discovery firms that can show both platform validation and tangible clinical assets. Clarification: S-1 filings lay out capital needs and risk factors ahead of public trading and are often the first formal indicator that a private biotech expects to access broad institutional liquidity.